Loading
Thoracic oncologist who led IMpower010, establishing adjuvant atezolizumab in lung cancer.
Enriqueta Felip is Head of the Thoracic Cancers Unit at Vall d'Hebron University Hospital in Barcelona and Professor at the Autonomous University of Barcelona. Her specialisms are lung cancer, targeted therapy and perioperative immunotherapy. She was principal investigator of IMpower010, reported in The Lancet, which tested adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer and established adjuvant immunotherapy in this setting. She is also a leader in trials of EGFR-, ALK- and KRAS-targeted therapy, including osimertinib. Her publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010) | Lancet | 2021 |
| CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery | New England Journal of Medicine | 2022 |
| CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer | New England Journal of Medicine | 2020 |
| DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer | New England Journal of Medicine | 2023 |
| KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation | New England Journal of Medicine | 2018 |
| MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer | New England Journal of Medicine | 2024 |
Patients newly diagnosed with EGFR-mutated advanced lung cancer now have a first-line option that improves survival over osimertinib, particularly if they have high-risk features. The trade-off is intravenous (now subcutaneous) infusions and considerably more skin, nail and clotting toxicity, so osimertinib alone remains reasonable for those who prioritise convenience and tolerability. Both this regimen and osimertinib plus chemotherapy (FLAURA2) are approved; there is no direct comparison.
Patients with small-cell lung cancer that has relapsed after chemotherapy now have a drug that works far better than topotecan or lurbinectedin, and it is the first T-cell engager approved for a solid tumour. Treatment requires inpatient monitoring for the first doses because of cytokine release syndrome, which most centres now manage on a short-stay basis. It does not yet apply to first-line treatment, where trials are ongoing.
Patients with operable stage II-III lung cancer without EGFR or ALK alterations should have chemo-immunotherapy discussed before surgery rather than only afterwards. Three pre-operative cycles do not compromise the operation and improve cure rates. Whether to continue immunotherapy after surgery, as the perioperative trials do, and whether patients with pCR need any further treatment, remain open questions.
The current first choice for ALK-positive lung cancer in most guidelines, and the strongest evidence in solid tumour oncology that a drug can be designed to work inside the brain. Five-year follow-up has since shown the majority of patients still progression-free.
Most patients with newly diagnosed advanced non-squamous lung cancer that lacks a targetable mutation should receive chemotherapy plus pembrolizumab; those with PD-L1 of 50% or more may reasonably receive pembrolizumab alone. About one in five patients is alive at five years, compared with roughly one in ten with chemotherapy alone. Patients with EGFR or ALK alterations were excluded and should have targeted therapy first.
Shares DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer, ALK, Osimertinib, EGFR.
Shares CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Osimertinib, Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, EGFR, Non-small-cell lung cancer.
Shares Osimertinib, Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer.
Shares CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer.
Shares CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer, EGFR, Non-small-cell lung cancer.
Shares DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer, MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer, EGFR, Non-small-cell lung cancer.